Quratis P/FCF

Que fait Quratis ? Quratis, Inc. generates revenue through the manufacture and sale of vaccines, including tuberculosis vaccines for adults and adolescents and COVID-19 vaccines, as well as peptide nucleic acid complex products. The company provides Cell Penetrating Peptide (CPP) platform services to clients in the pharmaceutical sector. Revenue streams are derived from the development and research activities related to vaccine products, with a focus on tuberculosis and COVID-19 vaccine research for adult and adolescent populations. Quratis targets pharmaceutical companies and research institutions seeking advanced vaccine development solutions. The company's CPP platform services are utilized by clients requiring innovative delivery systems for therapeutic applications. Revenue is generated through direct sales of vaccine products and service contracts for CPP platform usage, primarily serving the pharmaceutical industry segment focused on vaccine development and research. The firm's primary products include tuberculosis vaccines for adults and adolescents, COVID-19 vaccines, and peptide nucleic acid complex. These products are sold to pharmaceutical companies and research organizations. The company's revenue model combines product sales with service-based offerings, where the Cell Penetrating Peptide (CPP) platform services represent a key revenue stream alongside vaccine sales. Quratis est l'une des entreprises les plus populaires sur Eulerpool.